Reducing the dose of lenalidomide and discontinuing dexamethasone offers similar outcomes to continuous lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma, according to new research. “Our study shows, for the first time, that reducing the dose or intensity of treatment is a feasible option and produces similar outcomes as standard dose treatments for intermediate-fit patients,” ...
Steroid-sparing regimen performs well for elderly multiple myeloma patients
By Dave Levitan
25 Mar 2021